Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1
Ilaria Ambaglio,
Luca Malcovati,
Elli Papaemmanuil,
Coby M. Laarakkers,
Matteo G. Della Porta,
Anna Gallì,
Matteo C. Da Vià,
Elisa Bono,
Marta Ubezio,
Erica Travaglino,
Riccardo Albertini,
Peter J. Campbell,
Dorine W. Swinkels,
Mario Cazzola
Affiliations
Ilaria Ambaglio
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Luca Malcovati
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;Department of Molecular Medicine, University of Pavia, Italy
Elli Papaemmanuil
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
Coby M. Laarakkers
Department of Laboratory Medicine, Laboratory of Genetic, Endocrine and Metabolic Diseases, Radboud University Nijmegen Medical Center, The Netherlands;Hepcidinanalysis.com, Nijmegen, The Netherlands
Matteo G. Della Porta
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Anna Gallì
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;Department of Molecular Medicine, University of Pavia, Italy
Matteo C. Da Vià
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;Department of Molecular Medicine, University of Pavia, Italy
Elisa Bono
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;Department of Molecular Medicine, University of Pavia, Italy
Marta Ubezio
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;Department of Molecular Medicine, University of Pavia, Italy
Erica Travaglino
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Riccardo Albertini
Department of Diagnostic Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Peter J. Campbell
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
Dorine W. Swinkels
Department of Laboratory Medicine, Laboratory of Genetic, Endocrine and Metabolic Diseases, Radboud University Nijmegen Medical Center, The Netherlands;Hepcidinanalysis.com, Nijmegen, The Netherlands
Mario Cazzola
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;Department of Molecular Medicine, University of Pavia, Italy
Somatic mutations of the RNA splicing machinery have been recently identified in myelodysplastic syndromes. In particular, a strong association has been found between SF3B1 mutation and refractory anemia with ring sider-oblasts, a condition characterized by ineffective erythropoiesis and parenchymal iron overload. We studied the relationship between SF3B1 mutation, erythroid activity and hepcidin levels in myelodysplastic syndrome patients. Erythroid activity was evaluated through the proportion of marrow erythroblasts, soluble transferrin receptor and serum growth differentiation factor 15. Significant relationships were found between SF3B1 mutation and marrow erythroblasts (P=0.001), soluble transferrin receptor (P=0.003) and serum growth differentiation factor 15 (P=0.033). Serum hepcidin varied considerably, and multivariable analysis showed that the hepcidin to ferritin ratio, a measure of adequacy of hepcidin levels relative to body iron stores, was inversely related to the SF3B1 mutation (P=0.013). These observations suggest that patients with SF3B1 mutation have inappropriately low hepcidin levels, which may explain their propensity to parenchymal iron loading.